The present study suggested that the AFP promoter and the MK promoter are applicable to AFP-high- and AFP-low/nonproducing HCC, respectively, and the feasibility of both kinds of the promoter-based therapy will be investigated in clinical settings. The gene discussed is AFP; the disease is hepatocellular carcinoma.